Epithelioma Treatment Market By Treatment Type (Surgical Treatment, Mohs Micrographic Surgery, Radiation Therapy, Topical Medications, Systemic Therapy [Immunotherapy, Hedgehog Pathway Inhibitors, Chemotherapy], Photodynamic Therapy, Cryotherapy and Other Local Procedures); By Application (Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Locally Advanced Epithelioma, Metastatic Epithelioma, High-Risk Adjuvant Treatment, Recurrent Epithelioma); By End User (Hospitals, Dermatology Clinics, Oncology Centers, Ambulatory Surgical Centers, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Epithelioma Treatment Market: Procedure Volume Supports Scale as Immunotherapy Expands High-Value Care

The Global Epithelioma Treatment Market was valued at USD 2.29 billion in 2025 and is projected to reach USD 4.21 billion by 2032, growing at a CAGR of 9.1%, according to Strategic Market Research.

 

The Epithelioma Treatment Market in this report covers therapies for cutaneous basal cell carcinoma and cutaneous squamous cell carcinoma. Most revenue comes from recurring surgical procedures, while advanced cases support a smaller but higher-value systemic therapy segment. Benign sebaceous epithelioma and epithelial cancers arising in other organs fall outside the scope.

 

Epithelioma is not a standardized category in market reporting, reimbursement, cancer registries, or company disclosures. Basal cell carcinoma and cutaneous squamous cell carcinoma are also recorded differently across national databases. No independent public source provides a directly comparable global market value or CAGR for this treatment category. Demand is therefore assessed using claims, treatment spending, registered cases, eligible patients, reimbursement decisions, product approvals, and company investment.

 

The United States has the largest clearly documented treatment base. The American Cancer Society estimates that approximately 5.4 million basal and squamous cell skin cancers occur in about 3.3 million people annually, with some patients developing more than one lesion. Around eight in ten cases are basal cell carcinomas. The estimate relies on earlier epidemiological work because these common cancers are not routinely captured in U.S. cancer registries.

 

A Medical Expenditure Panel Survey analysis placed annual U.S. spending on non-melanoma skin cancer treatment at approximately USD 6.5 billion during 2016–2018. Office-based visits generated 74.8% of treatment costs, placing dermatology practices, specialist physician offices, and ambulatory providers at the centre of routine care.

 

Routine Local Treatment Accounts for Most Patient Volume

Most revenue-generating activity comes from local treatment of basal cell carcinoma and early cutaneous squamous cell carcinoma. Basal cell carcinoma leads by lesion volume, supported by its estimated 80% share of U.S. basal and squamous cell cancers and England’s substantially higher registered BCC count compared with cSCC.

England registered 158,934 basal cell carcinomas and 47,977 cutaneous squamous cell carcinomas in 2019. Total registered skin cancers rose from 177,677 in 2013 to 224,092 in 2019, although better registration may account for part of the increase alongside population ageing and exposure-related factors.

Surgery and other local procedures therefore generate the largest number of treatment episodes. Providers in this segment rely on patient throughput, referral networks, payer participation, and the capacity to manage repeated lesions rather than premium drug pricing. The difference between the estimated U.S. lesion count and the number of affected people indicates that a meaningful share of patients undergo more than one procedure.

Mohs surgery represents a higher-value procedural category for selected lesions where location, recurrence risk, or tissue preservation affects treatment choice. Medicare coverage depends on documented medical necessity, lesion characteristics, physician qualifications, and correct coding. CMS guidance requires providers to explain why standard excision or destruction was unsuitable when billing for covered Mohs services.

Reimbursement rules place limits on procedural revenue even when case volume rises. Dermatology groups with established payer contracts, referral access, trained personnel, and efficient clinic operations are better positioned to convert demand into sustainable revenue. Smaller providers may face capacity constraints, administrative costs, or claim denials that weaken the financial benefit of higher patient numbers.

 

Basal Cell Carcinoma Leads Volume, While cSCC Attracts More Pharmaceutical Value

Basal cell carcinoma is the dominant disease segment because of its high incidence and repeated local-treatment demand. Most patients remain within dermatology and outpatient pathways, while only a small proportion progress to disease requiring systemic treatment. Advanced BCC nevertheless supports a premium pharmaceutical category involving hedgehog pathway inhibitors and immunotherapy for patients with limited local-treatment options.

Payer decisions can restrict access despite regulatory authorization. NICE reported a list price of £6,285 for 28 capsules of vismodegib but did not recommend the treatment for NHS use because of evidence uncertainty and an unacceptable cost-effectiveness estimate. A proposed confidential discount did not overcome the appraisal concerns.

Advanced-BCC products therefore face narrow eligibility and significant reimbursement risk. Manufacturers need evidence that addresses payer budgets, duration of benefit, treatment sequencing, and real-world use rather than relying only on clinical response data or published list prices.

Cutaneous squamous cell carcinoma has a smaller lesion base but a larger share of treatment-related mortality and systemic-therapy opportunity. Most cases are treated locally, yet advanced disease supports branded immunotherapies, hospital oncology purchasing, specialty distribution, and patient-access programs.

NICE estimated approximately 31,400 annual cSCC cases in England in its 2022 resource model. Around 660 were expected to have metastatic disease and another 1,000 to have locally advanced disease that was unresectable or unsuitable for curative radiotherapy. After applying further eligibility assumptions, NICE estimated that 530 people could receive a PD-1 inhibitor and that about 310 would begin cemiplimab treatment annually at 58% uptake.

The patient funnel narrows sharply between diagnosis and systemic treatment. Disease stage, immune status, previous treatment, clinical suitability, reimbursement rules, and physician adoption reduce the number of eligible patients, even though revenue per treated patient is far higher than in routine local care.

 

Immunotherapy Is Increasing Competition in Advanced cSCC

Advanced cSCC has developed into a multi-product immunotherapy market. Cemiplimab received its original U.S. approval for metastatic or locally advanced cSCC in 2018. Pembrolizumab followed in 2020 for recurrent or metastatic disease that could not be cured with surgery or radiation. Cosibelimab entered the U.S. market in December 2024 for metastatic or locally advanced cSCC in patients who were not candidates for curative local treatment.

Direct branded competition has made hospital access, contracting, physician experience, patient selection, and treatment support more important. Approval does not guarantee uptake when therapies target similar patients and hospitals must account for formulary status, infusion capacity, and payer authorization.

Published prices illustrate how strongly value is concentrated in systemic treatment. NICE listed cemiplimab at £4,650 per 350 mg vial and estimated a one-year treatment cost of £80,877 before VAT. The NHS pays a lower confidential price, and treatment is limited to 24 months or stopped earlier if disease progresses.

Public list prices often exceed the revenue realized in centralized health systems. Net sales vary with negotiated discounts, treatment duration, patient eligibility, uptake, and national reimbursement terms. Applying list prices across the full eligible population can materially overstate the market opportunity.

 

Adjuvant cSCC Opens an Earlier Treatment Setting

The FDA approved cemiplimab in October 2025 for adults with cSCC at high risk of recurrence after surgery and radiation. The decision moved systemic treatment beyond metastatic and locally advanced disease into an earlier setting where patients have completed curative-intent local care but remain at elevated risk.

Adjuvant treatment expands the addressable population beyond patients who progress after surgery or radiotherapy. Dermatologists, surgeons, radiation oncologists, pathologists, medical oncologists, and multidisciplinary tumour boards now play a larger role in identifying eligible patients and directing referrals.

Country-level adoption will remain uneven. Regulatory approval does not guarantee public reimbursement, and national assessments may apply narrower risk definitions, duration limits, or confidential discounts. Manufacturers will need evidence on recurrence reduction, avoided subsequent treatment, healthcare utilization, and long-term outcomes to support coverage.

Regeneron’s broader Libtayo franchise demonstrates the commercial scale available to a successful multi-indication immunotherapy. Global Libtayo net sales reached approximately USD 1.45 billion in 2025, compared with USD 1.22 billion in 2024. The figure includes several cancer indications and cannot be treated as cSCC- or epithelioma-specific revenue, but it shows the financial resources supporting clinical development, market access, and expansion into earlier treatment settings.

 

Sun Pharma’s Entry Adds Pressure to Established Suppliers

Sun Pharma agreed in March 2025 to acquire Checkpoint Therapeutics for upfront consideration of up to USD 355 million, with additional contingent value linked to future regulatory milestones. The transaction centred on cosibelimab and strengthened Sun Pharma’s oncology-dermatology portfolio.

Cosibelimab became commercially available in the United States in January 2026 through a limited distribution network of authorized specialty distributors and one contracted specialty pharmacy, supported by a patient and healthcare-professional access program.

Sun Pharma’s acquisition provides direct evidence of corporate interest in advanced cSCC. The company bought an approved asset and commercial platform rather than relying only on internal development. Its dermatology presence may support physician engagement, but advanced disease also requires oncology relationships, infusion-centre access, reimbursement expertise, and specialty distribution.

Regeneron, Merck, and Sun Pharma now compete across overlapping advanced-cSCC populations. Formulary scrutiny and contracting pressure are likely to rise as suppliers increase spending on medical education, patient support, real-world evidence, and account management. New entrants must earn physician confidence and secure operational access rather than depend on approval status alone.

 

Dermatology Clinics Remain the Largest End-User Segment

Physician offices and dermatology clinics account for most treatment episodes because routine BCC and cSCC care is procedure-based and generally delivered outside inpatient hospitals. The 74.8% office-based share of U.S. non-melanoma skin cancer expenditure confirms the commercial importance of local dermatology networks.

Australia provides another measure of publicly reimbursed activity. Medicare paid 959,243 claims related to non-melanoma skin cancer in 2014, representing A$127.6 million in benefits. Although dated, the figures remain one of the clearest public indicators of paid treatment volume in a high-incidence market.

Hospitals and oncology centres treat fewer patients but generate more pharmaceutical value per episode. Advanced and adjuvant immunotherapies require institutional prescribing, infusion capacity, specialist monitoring, specialty distribution, and payer authorization. Suppliers therefore need separate commercial strategies for high-volume dermatology care and lower-volume oncology treatment.

 

North America Holds the Strongest Visible Position

North America leads on documented U.S. case volume, treatment expenditure, product approvals, and commercial launches. The estimated 5.4 million annual BCC and cSCC lesions create a large procedural base, while multiple FDA approvals support an expanding branded systemic-treatment segment.

Established specialist practices, Medicare and commercial insurance coverage, infusion networks, and specialty pharmacies support treatment access. Providers still manage inconsistent reimbursement, prior authorization, medical-necessity requirements, and varying payer policies.

Europe remains important because of its large registered patient base and structured reimbursement systems. England offers stronger visibility into BCC and cSCC volumes than U.S. registries, while NICE decisions show how eligible-patient estimates, cost-effectiveness, and confidential agreements determine access. European demand is substantial, but national payer decisions can delay or restrict commercial uptake.

Australia remains a large procedure-based market, supported by publicly reimbursed non-melanoma skin cancer activity. Its revenue structure is weighted more toward local treatment and fee schedules than the premium systemic opportunity attracting pharmaceutical investment in the United States.

Public data for many countries in Asia, Latin America, the Middle East, and Africa are less complete and not directly comparable. Lower reported incidence may reflect differences in diagnosis, access, registration, and population risk rather than limited treatment need.

 

Data Gaps Affect External Comparability

Basal and squamous cell skin cancers are excluded from several major cancer-registration systems. SEER does not routinely collect common cutaneous BCC, and GLOBOCAN incidence excludes BCC. Reported global non-melanoma skin cancer totals therefore do not represent the full treatment population.

Public sources also count different units, including patients, lesions, procedures, claims, treatment starts, and expenditure. One patient may generate several procedures, while systemic therapy can create repeated drug and infusion costs over many months.

Routine BCC and cSCC treatment, specialist procedures, advanced BCC medicines, advanced cSCC immunotherapy, and adjuvant cSCC therapy require separate revenue estimates. Each segment should reflect country-level reimbursement, net pricing, treatment duration, and eligible-patient volumes.

 

Market Outlook

Basal cell carcinoma and early cSCC will continue to account for most treatment volume in dermatology clinics, physician offices, and ambulatory centres. Revenue will depend on repeat lesions, available specialist capacity, referral patterns, and reimbursement.

Advanced and adjuvant cSCC will account for fewer patients but a growing share of pharmaceutical investment. Cosibelimab’s market entry, cemiplimab’s expansion into high-risk adjuvant disease, and continued competition from pembrolizumab are increasing spending on hospital access, payer engagement, and branded treatment differentiation.

Procedure-focused providers must manage staffing, clinic throughput, documentation, and payer compliance. Pharmaceutical suppliers face narrow eligibility, confidential discounts, country-specific reimbursement, and competition for oncology accounts. Companies that connect dermatology diagnosis and surgery with timely oncology referral will be better positioned as systemic treatment moves into earlier high-risk disease.

The Strategic Market Research valuation reflects the combined revenue opportunity across routine local treatment, specialist procedures, and systemic therapies. Country-level claims, procedure volumes, eligible-patient models, net pricing, and indication-specific sales estimates remain important supporting indicators because independent public sources do not report a directly comparable global epithelioma treatment market valuation.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.29 Billion
Revenue Forecast in 2032	USD 4.21 Billion
Overall Growth Rate	CAGR of 9.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Application, By End User, By Geography
By Treatment Type	Surgical Treatment, Mohs Micrographic Surgery, Radiation Therapy, Topical Medications, Systemic Therapy, Immunotherapy, Hedgehog Pathway Inhibitors, Chemotherapy, Photodynamic Therapy, Cryotherapy and Other Local Procedures
By Application	Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Locally Advanced Epithelioma, Metastatic Epithelioma, High-Risk Adjuvant Treatment, Recurrent Epithelioma
By End User	Hospitals, Dermatology Clinics, Oncology Centers, Ambulatory Surgical Centers, Specialty Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising burden of non-melanoma skin cancers, wider use of Mohs surgery for tissue-sparing treatment, growing adoption of immunotherapy and hedgehog pathway inhibitors, increasing dermatology screening programs, and expanding access to oncology-led care for advanced and recurrent epithelioma cases
Customization Option	Available upon request